Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673386 · ClinicalTrials.gov registry record · Phase 2
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
A Phase 2 study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01673386 is a Phase 2 study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT01673386, a Phase 2 study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
Interventions
- DRUG Sunitinib
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673386
The ClinicalTrials.gov registry entry for NCT01673386 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib is the first listed.
NCT01673386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673386 about?
NCT01673386 is a clinical study titled "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC". Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
What is the current status of trial NCT01673386?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2012-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01673386?
The interventions under investigation include: Sunitinib (DRUG), Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01673386?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.